Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

COMPLICATIONS OF ANTITUMOR TREATMENT , , ,

G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

 FGEI HPE RNRMU named after N.I. Pirogov of Russian MoH, Moscow, Russian Federation

ABSTRACT

The achieved nowadays success in oncohematology patients’ treatment is primarily associated with the development of targeted therapy, including invention of specific tyrosine kinase inhibitors for chronic myeloid leukemia treatment (imatinib, nilotinib and dasatinib,). However, along with the high efficacy, these medicines have certain toxicities. Cardiovascular complications of tyrosine kinase inhibitors therapy of chronic myeloid leukemia are described in this review article. Taking onto consideration the fact that therapy with these medicines can cause rear but serious side effects. It is necessary to consider the probability of cardiotoxicity, arterial occlusion of various diameter and pulmonary hypertension development before prescription. In order to minimize side effects patients examination is recommended before treatment initiation for recognition of initial cardiovascular diseases, as well as thorough control of cardiovascular condition throughout the treatment.

Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, cardiac toxicity, targeted therapy

 Read in  PDF (RUS)pdficon

REFERENCES

  1. Емелина Е.И., Шуйкова К.В., Сторожаков Г.И. и др. Поражения сердца при лечении современными противоопухолевыми препаратами и лучевые повреждения сердца у больных с лимфомами. Клин. онкогематол. 2009; 2(2): 152–60. [Emelina E.I., Shuikova K.V., Storozhakov G.I. i dr. Porazheniya serdtsa pri lechenii sovremennymi protivoopukholevymi preparatami i luchevye povrezhdeniya serdtsa u bol’nykh s limfomami (Heart diseases in the modern anti-tumor agent treatment and radiation-induced heart lesions in lymphoma patients). Klin. onkogematol. 2009; 2(2): 152–60.]
  2. Гендлин Г.Е., Сторожаков Г.И., Шуйкова К.В. и др. Острые сердечнососудистые события во время применения противоопухолевых химиопрепаратов: клинические наблюдения. Клин. онкогематол. 2011; 4(2): 155–64. [Gendlin G.E., Storozhakov G.I., Shuikova K.V. i dr. Ostrye serdechnososudistye sobytiya vo vremya primeneniya protivoopukholevykh khimiopreparatov: klinicheskie nablyudeniya (Acute cardiovascular events during treatment with anti-tumor chemotherapeutic agents: clinical observations). onkogematol. 2011; 4(2): 155–64.]
  3. Емелина Е.И., Сторожаков Г.И., Гендлин Г.Е. и др. Случай антрациклин-индуцированной кардиомиопатии после лечения диффузной крупноклеточной В-клеточной лимфомы по схеме АСОР и лучевой терапии. Сердечная недостаточность 2006; 4(38): 202–4. [Emelina E.I., Storozhakov G.I., Gendlin G.E. i dr. Sluchai antratsiklin-indutsirovannoi kardiomiopatii posle lecheniya diffuznoi krupnokletochnoi V-kletochnoi limfomy po skheme ASOR i luchevoi terapii (A case of an anthracycline-induced cardiomyopathy after the ACOP treatment of diffuse large B-cell lymphoma). Serdechnaya nedostatochnost’ 2006; 4(38): 202–4.]
  4. Hare J.M. The Dilated, Restrictive, and Infiltrative Cardiomyopathies. In: Braunwald’s heart disease: A Textbook of Cardiovascular Medicine, 8th Edition, 2008.
  5. ACC/AHA 2005 Guidelines Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
  6. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J. Am. Soc. Echocardiogr. 2011; 24: 229–67.
  7. Nuclear Cardiology and Cardiac CT. Berlin, May 5–8, 2013.
  8. Домнинский Д.А. Основы таргетной терапии. Онкогематология 2012; 1: 46–54. [Domninskii D.A. Osnovy targetnoi terapii (Fundamentals of targeted therapy). Onkogematologiya 2012; 1: 46–54.]
  9. Hughes T.P., Kaeda J., Branford S. et al. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. New Engl. J. Med. 2003; 349: 1423–32.
  10. National comprehensive cancer network NCCN clinical practice guidelines in oncology: Chronic myelogenous leukemia: Version 2. Fort Washington, PA,
  11. Chen M.H., Kerkela R., Forse T. et al. Mechanisms of cardiac dysfunction associated with tirosine kinase inhibitor cancer therapeutics. Circulation 2008; 118: 84–95.
  12. Kerkela R., Grazette I., Yacolti R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006; 12(8).
  13. Ederhy S., Izzedine H., Massard C. et al. Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Crit. Rev. Oncol. Hematol. 2011: 369–79.
  14. Pinilla-Ibarz J., Cortes J., Mauro M.J. et al. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 2011; 117: 688–97.
  15. Kantarjian H.M., Shah N.P., Cortes J.E. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123–9.
  16. Porkka K., Khoury H.J., Paquette R. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377–86.
  17. Kantarjian H., Shah N.P., Hochhaus A. et al. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New Engl. J. Med. 2010.
  18. Saglio G., Hochhaus A., Cortes J.E. et al. Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CMLCP): Analysis of the DASISION Trial. ASH 2010. Poster 2286.
  19. Rasheed W., Flaim B., Symour J.F. et al. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk. Res. 2009; 33: 860–9.
  20. EMEA: Sprycel-Scientific discussion. European Public Assessment Report (EPAR 2011).
  21. Quintas-Cardama A., Kantarjian H., O’Brien S. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. Clin. Oncol. 2007; 25(25): 3908–14.
  22. Mattei D., Feola M., Orzan F. et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009; 43(12): 967–8.
  23. Dumitrescu D., Seck C., ten Freyhaus H. et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Respir. J. 2011; 38(1): 218–20.
  24. Hennigs J.K., Keller G., Baumann H.J. et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm. Med. 2011; 23: 11–30.
  25. Orlandi E.M., Rocca B., Pazzano A.S. et al. Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukemia. Leuk. Res. 2012; 36(81): 4–6.
  26. Breccia M., Efficace F., Alimena G. et al. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who’s afraid of the big bad wolf? Res. 2012; 36: 813–4.
  27. Montani D., Bergot E., Ganter S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125(17): 2128–37.
  28. Philibert L., Cazorla C., Peyrire H. et al. Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib (Abstract). Fundam. Clin. Pharmacol. 2011; 25(Suppl. 1): 95.
  29. Aichberger K.J., Herndlhofer S., Schernthaner G.-H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Hematology 2011; 86: 533–9.